Alinia is nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL, with an FDA-labeled clinical role involving diarrhea caused by Giardia lamblia or Cryptosporidium parvum in FDA-labeled populations. For U.S. prescription shoppers, the most important task is identifying the exact medicine before comparing pharmacy services or insurance. The branded name must be read alongside active ingredient, dosage form, route and labeled indication. This page focuses on Alinia as a distinct pharmaceutical product, not on indiscriminate shopping for every product containing a similar ingredient or sharing a broadly related clinical purpose.
The practical distinguishing feature is tablet and reconstituted-suspension formats with different age cutoffs. A complete U.S. pharmacy order therefore needs Alinia tablet 500 mg versus for-oral-suspension 100 mg/5 mL after mixing; a listing that omits those details can be misleading. In particular, it would be wrong to mistake the item for oral metronidazole for other protozoal diseases or different liquid concentrations. Neither the existence of FDA labeling nor a retail product-page image establishes current stock. A real prescriber must determine medical suitability, and a licensed pharmacy must confirm the item and instructions before dispensing.
This brand guide complements buy nitazoxanide and metronidazole vs nitazoxanide for giardia, which address a different decision level. Here the emphasis is on the labeled Alinia form, the documentation a pharmacy should check, and the safety issue of age-specific labeling, stool diagnosis and limited evidence in immunodeficiency. No unverified inventory count, pharmacy ranking, universal price, discount code or self-prescribing shortcut is implied. When a product change is proposed, the patient and prescriber should confirm that the new order reflects an appropriate clinical decision rather than a misleading drug-name match.
For Alinia, the primary dispensing comparison is between a 500 mg nitazoxanide tablet and a suspension that becomes 100 mg per 5 mL after reconstitution. The name on the box alone is insufficient: the prescription, patient age, clinical indication and measured concentration determine whether the requested dosage form fits the FDA label. The table highlights these checkpoints without suggesting that a pharmacist should convert a child’s suspension prescription into tablets.
Alinia has labeled use for specified Giardia and Cryptosporidium diarrheal infections, not every intestinal symptom or every infection for which metronidazole is prescribed. Its indication and age-related restrictions are more useful than generic online-pharmacy advertising. A dispensing decision still depends on clinical evaluation, the exact prescription and the shelf life of any liquid that has already been mixed.
| Checkpoint | Alinia: intended product | Potential error to avoid |
|---|---|---|
| Product identity | nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL | oral metronidazole for other protozoal diseases or different liquid concentrations |
| Treatment target | diarrhea caused by Giardia lamblia or Cryptosporidium parvum in FDA-labeled populations | Treating a different diagnosis or rosacea symptom |
| Defining feature | tablet and reconstituted-suspension formats with different age cutoffs | Matching on ingredient word alone |
| Prescription details | Alinia tablet 500 mg versus for-oral-suspension 100 mg/5 mL after mixing | A web listing with missing strength or form |
| Pharmacy dispensing | Valid prescription, correct package, patient counseling | No-prescription offers or unverifiable merchants |
| Substitution | FDA approval/TE and prescriber authorization as applicable | Automatic swap across dosage form or active ingredient |
| Safety review | age-specific labeling, stool diagnosis and limited evidence in immunodeficiency | Assuming similar products share warnings |
| Price or insurance | Actual pharmacy claim and package-specific check | Guaranteed savings or stock availability |
Alinia contains nitazoxanide and is indicated for diarrhea caused by Giardia lamblia or Cryptosporidium parvum in the labeled populations. That scope is not identical to all the infections for which oral metronidazole may be prescribed.
For a person with persistent diarrhea, confirming the organism matters more than selecting a familiar antiprotozoal name. Clinical history, testing and hydration concerns need evaluation. For more detail about the related but distinct decision, see metronidazole for giardiasis; that page does not authorize any substitution.
The Alinia tablet label is for patients 12 years of age and older, whereas the oral suspension has a labeled pediatric role beginning at one year of age. The tablet contains 500 mg, an amount greater than the recommended per-dose amount in children 11 and younger. A pharmacy should never replace a pediatric suspension order with a tablet on the assumption that the brand name makes the forms interchangeable.
The correct oral suspension concentration after reconstitution is 100 mg per 5 mL. Age and the exact prescription determine the intended amount; caregivers should use the supplied measurement device and follow the prescriber’s directions rather than estimating doses from tablet strength or spoonfuls. Even when a patient is 12 or older and could receive either form under its labeling, the pharmacy needs an order for the intended product.
Alinia oral suspension is supplied as powder and becomes 100 mg/5 mL only after preparation according to its manufacturer’s directions. Its labeling specifies measuring the prescribed amount of water for reconstitution, shaking the mixture and giving instructions for shaking before use. The steps belong in pharmacy preparation and dispensing procedures, not in consumer guesswork from a photograph of a bottle.
The official label states that reconstituted suspension may be kept for seven days at room temperature, after which unused suspension must be discarded. This limit is not the same as the expiration date of an unopened powder bottle or a tablet package. Caregivers should ask the pharmacy to mark the preparation date and demonstrate use of an appropriate oral syringe or measuring device.
Nitazoxanide has an FDA-labeled Giardia indication. Oral metronidazole is also used clinically for Giardia, but the precise U.S. labeling and treatment context differ. The existence of two possible treatments does not justify exchanging them without a diagnosis and prescription.
Their adverse effects, dosing and patient suitability require individual assessment. The condition-specific comparison clarifies why one clinician may choose a different agent. For more detail about the related but distinct decision, see metronidazole vs nitazoxanide for giardia; that page does not authorize any substitution.
Alinia labeling includes an important limitation regarding effectiveness for Cryptosporidium in HIV-infected or immunodeficient individuals. Clinical follow-up for persistent symptoms or immune compromise cannot be replaced by an online order.
A pharmacy should dispense the exact dosage form and counsel the caregiver or patient about administration. Availability and reimbursement must be verified with that pharmacy and health plan.
Before anyone purchases Alinia, the clinician should verify the diagnosis associated with diarrhea caused by Giardia lamblia or Cryptosporidium parvum in FDA-labeled populations and review why nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL was selected. The dose, dosage form and route are intentional parts of the order. A patient’s prior responses, other medications, and any concern involving age-specific labeling, stool diagnosis and limited evidence in immunodeficiency can change what is appropriate. This cannot be resolved by comparing brand photographs or prices.
A newly prescribed product may also require counseling that is not found on an older prescription. If the patient previously used oral metronidazole for other protozoal diseases or different liquid concentrations, the clinician must decide how the new therapy changes the care plan. Incomplete medication histories can conceal adverse reactions or interactions. Ask for a clear indication and complete instructions rather than relying on retailer advertising.
A legitimate dispenser will verify a valid prescription for Alinia, inspect the precise Alinia tablet 500 mg versus for-oral-suspension 100 mg/5 mL after mixing and confirm the actual item that will be dispensed. For online orders, the pharmacy should be licensed where required, maintain a U.S. business identity, require prescriber authorization and make pharmacist counseling available. A seller who offers the product without a prescription is a warning sign, not an access advantage.
At pickup or delivery, check the label against the prescribed medicine: nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL. The packaging must be intact and the route clear. If the item instead resembles oral metronidazole for other protozoal diseases or different liquid concentrations, stop and clarify with the pharmacist before use. Neither DailyMed, an FDA application listing nor a product-search result proves that a particular store has an item waiting for shipment.
A patient comparing Alinia quotes should first establish whether the claim concerns 500 mg tablets or powder for the 100 mg/5 mL oral suspension. Those two forms are not interchangeable on a per-package basis, and the insurer may classify them differently. A generic nitazoxanide product may be discussed only after checking its actual approval, dosage form and relevant pharmacy substitution rules.
For pediatric prescriptions, age-specific labeling can rule out a tablet even when the drug name matches. If a plan does not cover the written form, the prescriber needs to evaluate any alternative, while the pharmacist confirms concentration, measuring device and whether reconstituted product can be supplied with sufficient remaining use life. No formulary listing or NDC indicates live inventory.
For Alinia, delivery checks depend on whether the prescription is for 500 mg tablets or a prepared 100 mg/5 mL oral suspension. The suspension has a limited seven-day use period after mixing, making preparation status and shipping arrangements especially important. Ask the pharmacist when the liquid was reconstituted and how much labeled shelf life remains when received.
Persistent or recurrent diarrhea may require reassessment of the diagnosis, dehydration status or other causes rather than an automatic antibiotic refill. Alinia’s FDA-labeled indications involve specific protozoal infections; it should not be repurposed for every cause of diarrhea or substituted for metronidazole used for a different infection.
Alinia is FDA-labeled for diarrhea caused by Giardia lamblia within its specified age groups.
The 500 mg tablets are for patients aged 12 years and older; the suspension has different pediatric labeling.
No. Nitazoxanide and metronidazole are different medicines with distinct indications and forms.
No. The U.S. nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL is a prescription drug and requires lawful prescribing and pharmacy dispensing.
The label must identify Alinia tablet 500 mg versus for-oral-suspension 100 mg/5 mL after mixing, with patient-specific directions and a valid prescription.
No. Do not treat oral metronidazole for other protozoal diseases or different liquid concentrations as an approved equivalent merely because wording or ingredients look related.
No availability claim can be made from a brand listing. Ask a licensed pharmacy to check the exact nitazoxanide oral 500 mg tablets and powder for suspension yielding 100 mg/5 mL.
Not automatically. FDA therapeutic-equivalence data, the exact dosage form and the prescription and state rules must support the substitution.
Not without clinical review. The distinguishing feature is tablet and reconstituted-suspension formats with different age cutoffs, and a change may alter treatment.
Have the pharmacy run a current claim or quote for the exact product and package; do not rely on general savings claims.